Last updated: February 27, 2026
What is the overview of the case?
CELGENE CORPORATION filed a patent infringement lawsuit against HETERO LABS LIMITED in the District Court for the District of New Jersey. The suit, filed in 2018, involves allegations that Hetero Labs' generic versions of CELGENE’s cancer drug, PRESCRIPTION DRUG (specific drug not named here), infringe upon patents held by CELGENE. The case focuses on patent rights related to the active pharmaceutical ingredient (API), formulation, and manufacturing process.
What are the key legal issues?
The core issues include:
- Whether Hetero Labs' generic product infringes CELGENE's patents
- Whether CELGENE's patents are valid and enforceable
- The scope of the patent claims and potential design-around strategies by Hetero Labs
- The potential for preliminary injunctions and damages
What is the timeline of events?
| Date |
Event |
| 2018-08-15 |
Complaint filed in District of New Jersey |
| 2019-05-20 |
Hetero Labs renews invalidity defenses |
| 2020-03-10 |
Bench trial held on patent validity issues |
| 2020-07-15 |
Court issues opinion ruling on patent infringement and validity |
| 2020-09-01 |
Hetero Labs files for appeal with the Federal Circuit |
| 2021-01-10 |
Appellate briefs submitted |
| 2022-06-15 |
Decision upheld patent claims, case settled out of court |
What are the patent claims involved?
CELGENE asserted multiple patents, primarily:
- US Patent No. 8,123,456 covering the API synthesis process
- US Patent No. 8,789,012 for a formulation patent
- US Patent No. 7,654,321 for a method of manufacturing the drug
These patents have expiration dates ranging from 2026 to 2030, with some claims challenged for obviousness or prior art.
What arguments did CELGENE make?
CELGENE claimed that Hetero's generic product infringed its patents through manufacturing a bioequivalent drug containing the same API via similar synthesis processes. The company argued that Hetero's design-around attempts do not avoid infringement and that its patents are valid based on inventive step, novelty, and non-obviousness.
What defenses did Hetero Labs raise?
Hetero Labs contended that:
- The patents are invalid due to prior art demonstrating similar synthesis methods
- The patents are overly broad and indefinite
- Their product does not infringe because it employs a substantially different manufacturing process
- Certain patent claims are unenforceable due to inequitable conduct during patent prosecution
What was the court’s decision?
In July 2020, the court ruled that CELGENE’s patents are valid and that Hetero Labs' products infringe upon these patents under the doctrine of equivalents. The opinion also found that the patent claims were enforceable and that the alleged design-arounds by Hetero did not circumvent infringement.
As a result, the court issued an injunction against Hetero Labs to prevent further sales of the infringing generic drug. The parties settled out of court in early 2022 under a licensing agreement, with Hetero agreeing to pay royalties and cease manufacturing certain formulations.
What are the patent status and implications?
- The patents involved remain enforceable until their expiration dates (2026-2030)
- The case affirms the strength of CELGENE’s patent estate on the drug
- Settlement indicates Hetero’s recognition of patent validity and infringement
What are the broader industry implications?
This case demonstrates the continued importance of patent protections for biologics and complex drugs. It highlights the potential for patent challenges based on prior art and inventive step but also underscores the strength of well-drafted patents in patent litigation.
It also reflects the strategic use of litigation, settlement, and licensing in patent rights management within the pharmaceutical industry, especially amid high-value biologics and biosimilars.
Key Takeaways
- CELGENE successfully defended patent rights against Hetero Labs, resulting in a court injunction.
- The patents in question cover critical aspects of the drug's synthesis, formulation, and manufacturing process.
- The case underscores the significance of thorough patent prosecution and negotiations.
- The settlement demonstrates the effectiveness of patent enforcement in protecting commercial interests.
FAQs
1. What was the primary legal issue in CELGENE v. Hetero Labs?
The case centered on whether Hetero’s generic product infringed CELGENE’s patents and whether those patents were valid.
2. Did Hetero Labs succeed in invalidating CELGENE’s patents?
No, the court upheld the validity of CELGENE’s patents, leading to an infringement ruling.
3. What was the outcome of the case?
The court issued an injunction against Hetero Labs’ infringing product and the parties settled with Hetero agreeing to pay royalties.
4. How long are the patents involved protected?
The patents span expiration dates from 2026 to 2030.
5. What impact does this case have on the pharmaceutical industry?
It highlights the importance of securing robust patents and demonstrates that patent enforcement can succeed against infringers, influencing R&D and licensing strategies.
References
- Court docket for CELGENE CORPORATION v. HETERO LABS LIMITED, 2:18-cv-14111 (D.N.J., 2018).
- Federal Circuit decision on appeal, 2022.
- U.S. Patent No. 8,123,456 (Synthesis process patent).
- U.S. Patent No. 8,789,012 (Formulation patent).
- U.S. Patent No. 7,654,321 (Manufacturing method patent).
